MCID: OCL022
MIFTS: 52

Ocular Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 12 74 20 54 15 17
Intraocular Melanoma 12 20 6
Malignant Melanoma of Eye 71
Melanoma of the Uvea 20
Melanoma of Eye 12
Uveal Melanoma 20
Eye Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1752
UMLS 71 C0558356

Summaries for Ocular Melanoma

GARD : 20 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract. The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors.

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to bap1 tumor predisposition syndrome and exanthem. An important gene associated with Ocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Ranibizumab and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are homeostasis/metabolism and growth/size/body region

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : 74 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 bap1 tumor predisposition syndrome 32.5 BRCA2 BAP1
2 exanthem 30.2 VEGFA TNF KIT IL2
3 malignant conjunctival melanoma 30.2 NRAS GNAQ GNA11
4 plasmacytoma 30.2 VEGFA IL2 CDKN2A
5 malignant peritoneal mesothelioma 30.2 CDKN2A BAP1
6 posterior scleritis 30.1 VEGFA TNF
7 kidney cancer 29.8 VEGFA TNF IL2 CDKN2A
8 pancreatic adenocarcinoma 29.8 VEGFA KIT CDKN2A BRCA2
9 glioblastoma 29.8 VEGFA TERT NRAS KIT CDKN2A BRCA2
10 cystitis 29.8 VEGFA TNF KIT IL2
11 leiomyosarcoma 29.7 VEGFA S100B KIT CDKN2A
12 adenocarcinoma 29.6 VEGFA KIT CDKN2A BRCA2 AXL
13 malignant spindle cell melanoma 29.6 NRAS KIT GNAQ GNA11 CDKN2A
14 neurofibromatosis, type i 29.5 S100B NRAS KIT CDKN2A BRCA2
15 adenoid cystic carcinoma 29.4 VEGFA S100B KIT CDKN2A
16 neuroblastoma 29.2 VEGFA TNF TERT NRAS KIT IL2
17 hemangioma 29.2 VEGFA KIT GNAQ GNA11
18 basal cell carcinoma 29.2 VEGFA TNF TERT MC1R KIT IL2
19 peripheral nervous system disease 29.1 VEGFA TNF S100B KIT IL2 CDKN2A
20 myelodysplastic syndrome 29.0 VEGFA TNF TERT NRAS KIT IL2
21 ocular cancer 29.0 MC1R IL2 GNAQ GNA11 CDKN2A BRCA2
22 rhabdomyosarcoma 28.9 VEGFA TNF S100B NRAS KIT CDKN2A
23 melanoma, cutaneous malignant 1 28.8 TERT NRAS MC1R KIT GNAQ GNA11
24 leukemia, acute myeloid 28.6 VEGFA TNF TERT NRAS KIT IL2
25 uveal disease 28.5 VEGFA TNF NRAS IL2 GNAQ GNA11
26 melanoma, uveal 28.2 VEGFA TERT S100B PTP4A3 NRAS MC1R
27 lung cancer 28.1 VEGFA TNF TERT NRAS MAGEA3 MAGEA1
28 melanoma 28.0 VEGFA TNF TERT S100B NRAS MC1R
29 mucosal melanoma 27.9 VEGFA TERT NRAS KIT IL2 GNAQ
30 skin melanoma 27.9 VEGFA TNF TERT S100B NRAS MC1R
31 skin carcinoma 27.7 VEGFA TNF TERT NRAS MC1R KIT
32 necrotic uveal melanoma 11.6
33 mixed cell uveal melanoma 11.5
34 tumor predisposition syndrome 11.3
35 spindle cell intraocular melanoma 11.3
36 uveal epithelioid cell melanoma 11.3
37 iris spindle cell melanoma 11.1
38 severe combined immunodeficiency 10.5
39 macular retinal edema 10.4
40 cervical adenoid cystic carcinoma 10.3 KIT CDKN2A
41 melphalan allergy 10.3 NRAS IL2
42 laryngeal small cell carcinoma 10.3 KIT CDKN2A
43 maxillary sinus benign neoplasm 10.3 KIT CDKN2A
44 herpes simplex 10.3
45 peritoneum cancer 10.3 CDKN2A BRCA2 BAP1
46 retroperitoneal hemangiopericytoma 10.3 VEGFA KIT
47 bilateral breast cancer 10.3 MC1R CDKN2A BRCA2
48 bowenoid papulosis 10.3 TERT CDKN2A
49 cecal benign neoplasm 10.3 TERT CDKN2A
50 cecum adenoma 10.3 TERT CDKN2A

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 AXL BAP1 BRCA2 CD63 CDKN2A GNA11
2 growth/size/body region MP:0005378 10.38 AXL BAP1 BRCA2 CDKN2A GNA11 GNAQ
3 hematopoietic system MP:0005397 10.37 AXL BAP1 BRCA2 CDKN2A GNA11 GNAQ
4 behavior/neurological MP:0005386 10.35 BRCA2 CD63 CDKN2A GNA11 GNAQ IL2
5 immune system MP:0005387 10.34 AXL BAP1 BRCA2 CDKN2A GNA11 GNAQ
6 endocrine/exocrine gland MP:0005379 10.33 AXL BAP1 BRCA2 CDKN2A GNA11 GNAQ
7 cardiovascular system MP:0005385 10.31 AXL BAP1 CDKN2A GNA11 GNAQ IL2
8 digestive/alimentary MP:0005381 10.26 BAP1 BRCA2 CD63 CDKN2A IL2 KIT
9 integument MP:0010771 10.26 AXL BAP1 BRCA2 CDKN2A GNA11 GNAQ
10 neoplasm MP:0002006 10.14 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
11 liver/biliary system MP:0005370 10.09 AXL CDKN2A GNA11 IL2 KIT NRAS
12 limbs/digits/tail MP:0005371 10.06 BRCA2 GNA11 GNAQ KIT MC1R NRAS
13 no phenotypic analysis MP:0003012 10.02 BAP1 CDKN2A IL2 KIT MC1R NRAS
14 normal MP:0002873 10.02 AXL BRCA2 GNA11 GNAQ KIT NRAS
15 reproductive system MP:0005389 9.85 AXL BAP1 BRCA2 CDKN2A IL2 KIT
16 pigmentation MP:0001186 9.73 CDKN2A GNA11 GNAQ KIT MC1R NRAS
17 respiratory system MP:0005388 9.61 BAP1 CDKN2A GNA11 GNAQ IL2 KIT
18 skeleton MP:0005390 9.32 AXL BRCA2 CDKN2A GNA11 GNAQ KIT

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Melphalan Approved Phase 3 148-82-3 4053 460612
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Fotemustine Investigational Phase 3 92118-27-9
5 Immunosuppressive Agents Phase 3
6 Immunologic Factors Phase 3
7 Alkylating Agents Phase 3
8 Mitogens Phase 3
9 Endothelial Growth Factors Phase 3
10 Vaccines Phase 3
11 Liver Extracts Phase 3
12
Sodium citrate Approved, Investigational Phase 2 68-04-2
13
Tamoxifen Approved Phase 2 10540-29-1 2733526
14
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
15
Gemcitabine Approved Phase 2 95058-81-4 60750
16
Pancrelipase Approved, Investigational Phase 2 53608-75-6
17
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
18
Pasireotide Approved Phase 2 396091-73-9 9941444
19
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
20
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
21
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
22
Aluminum sulfate Approved Phase 2 10043-01-3
23
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
24
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
25
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
26
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
27
Entrectinib Approved, Investigational Phase 1, Phase 2 1108743-60-7 25141092
28
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
29
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
30
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
31
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166 2942
32
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
33
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
34 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
35
Carmustine Approved, Investigational Phase 2 154-93-8 2578
36
Ipilimumab Approved Phase 2 477202-00-9
37
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
38
nivolumab Approved Phase 2 946414-94-4
39
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
40
Lenalidomide Approved Phase 2 191732-72-6 216326
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
45
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
46
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
47
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
48
Acyclovir Approved Phase 2 59277-89-3 2022
49
Mesna Approved, Investigational Phase 2 3375-50-6 598
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
2 Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Unknown status NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
3 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
6 A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
7 A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA Recruiting NCT01983748 Phase 3
8 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
9 A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma Active, not recruiting NCT02678572 Phase 3
10 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
11 Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
12 Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse Terminated NCT00036816 Phase 3
13 Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma Unknown status NCT01217398 Phase 2 temozolomide
14 A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
15 A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
16 Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
17 Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
18 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma Completed NCT00738361 Phase 2 nab-paclitaxel
20 A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
21 A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
22 A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
23 Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
24 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
25 Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Completed NCT00661622 Phase 2 GM-CSF
26 A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Completed NCT01551459 Phase 2 Dacarbazine;Sunitinib
27 A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
28 A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
29 Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
30 Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
31 Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
32 Phase II Study of IMC-A12 in Metastatic Uveal Melanoma Completed NCT01413191 Phase 2
33 Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma Completed NCT00089219 Phase 1, Phase 2
34 Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma Completed NCT00089206 Phase 2
35 MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
36 A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma Completed NCT00031733 Phase 2 alum adjuvant
37 A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
38 Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma Completed NCT00238329 Phase 2 thalidomide
39 An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
40 An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
41 A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma Completed NCT00003339 Phase 2
42 A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
43 A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma Completed NCT00027742 Phase 2 temozolomide
44 A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
45 THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11) Completed NCT01355120 Phase 2 Ipilimumab
46 A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
47 Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma Completed NCT00085306 Phase 2
48 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma Completed NCT00062933 Phase 2
49 A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
50 Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma Recruiting NCT04589832 Phase 1, Phase 2 PAC-1;Entrectinib

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Anatomical Context for Ocular Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

19
Eye

MalaCards organs/tissues related to Ocular Melanoma:

40
Eye, Liver, Retina, Endothelial, T Cells, Skin, Bone Marrow

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 1035)
# Title Authors PMID Year
1
Cancer-related diseases of the eye: the role of calcium and calcium-binding proteins. 61 54
15336963 2004
2
Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. 54 61
15326139 2004
3
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. 54 61
12883368 2003
4
BRCA2 mutations in a population-based series of patients with ocular melanoma. 54 61
12385017 2002
5
Expression of MAGE genes in ocular melanoma cell lines. 61 54
9220316 1997
6
Single shot echo planar imaging (ssEPI) vs single shot turbo spin echo (ssTSE) DWI of the orbit in patients with ocular melanoma. 61
33264035 2021
7
Long-term results of visual function in posterior uveal melanoma patients treated with I125 episcleral brachytherapy in a Spanish referral Ocular Oncology Unit. 61
33567036 2021
8
m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma. 61
33601055 2021
9
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study. 61
32761328 2021
10
Ocular melanoma incidence rates and trends in the United States, 2001-2016. 61
32350449 2021
11
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. 61
33211315 2021
12
In-vivo imaging for assessing tumor growth in mouse models of ocular melanoma. 61
33406396 2021
13
EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for 125I Collaborative Ocular Melanoma Study eye plaques. 61
33187821 2021
14
Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre. 61
33242884 2021
15
In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. 61
33479026 2021
16
The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). 61
33060121 2021
17
Thermography in clinical ophthalmic oncology. 61
33470338 2021
18
Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. 61
33396957 2020
19
ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma. 61
32683632 2020
20
F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence. 61
33380688 2020
21
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆. 61
33385520 2020
22
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. 61
32564137 2020
23
Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma. 61
33235338 2020
24
Is it necessary to perform eye examination for patients with cutaneous atypical nevi? 61
33142003 2020
25
Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort. 61
33004998 2020
26
Extrafoveal Müller cells detection in vivo in the human retina: A pilot study based on optical coherence tomography. 61
32777210 2020
27
An Artificial CTCF Peptide Triggers Efficient Therapeutic Efficacy in Ocular Melanoma. 61
32775616 2020
28
Optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques: A simulation study based on current clinical practice. 61
32656945 2020
29
Oral isotretinoin and topical retinoid use in a series of young patients with ocular melanoma. 61
32760850 2020
30
Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. 61
31446147 2020
31
Evolution of Care of Orbital Tumors with Radiation Therapy. 61
33072488 2020
32
Cutaneous Signs and Risk Factors for Ocular Melanoma. 61
32871165 2020
33
Personalized treatment planning in eye brachytherapy for ocular melanoma: Dosimetric analysis on ophthalmic structure at risk. 61
32738776 2020
34
Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. 61
33293968 2020
35
Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. 61
32718045 2020
36
Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter? 61
32081600 2020
37
AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. 61
31883269 2020
38
Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy. 61
32401016 2020
39
Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5. 61
32509767 2020
40
Anthropometry in the immunotherapy of cutaneous and ocular melanomas. 61
32685786 2020
41
Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort. 61
32321466 2020
42
Electrochemotherapy in 3D Ocular Melanoma Spheroids using a Customized Electrode. 61
32421010 2020
43
The Collaborative Ocular Melanoma Study Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. 61
32200814 2020
44
The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19. 61
32200815 2020
45
Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study. 61
31626886 2020
46
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. 61
30924738 2020
47
Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. 61
31425478 2020
48
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. 61
32087721 2020
49
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. 61
31686137 2020
50
VEGFR1-Targeted Contrast-Enhanced Ultrasound Imaging Quantification of Vasculogenic Mimicry Microcirculation in a Mouse Model of Choroidal Melanoma. 61
32704424 2020

Variations for Ocular Melanoma

ClinVar genetic disease variations for Ocular Melanoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GNA11 NM_002067.5(GNA11):c.626A>C (p.Gln209Pro) SNV Likely pathogenic 376001 rs1057519742 19:3118942-3118942 19:3118944-3118944
2 GNAQ NM_002072.5(GNAQ):c.626A>C (p.Gln209Pro) SNV Likely pathogenic 375957 rs121913492 9:80409488-80409488 9:77794572-77794572
3 GNAQ NM_002072.5(GNAQ):c.626A>T (p.Gln209Leu) SNV Likely pathogenic 375955 rs121913492 9:80409488-80409488 9:77794572-77794572
4 GNA11 NM_002067.5(GNA11):c.626A>T (p.Gln209Leu) SNV Likely pathogenic 376002 rs1057519742 19:3118942-3118942 19:3118944-3118944
5 GNAQ NM_002072.5(GNAQ):c.625_626delinsTT (p.Gln209Leu) Indel Likely pathogenic 376311 rs1057519853 9:80409488-80409489 9:77794572-77794573

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 VEGFA TNF TERT NRAS KIT IL2
2
Show member pathways
12.6 VEGFA TNF NRAS GNAQ GNA11 CDKN2A
3
Show member pathways
12.59 TERT NRAS KIT CDKN2A BRCA2
4
Show member pathways
12.4 NRAS MC1R KIT GNAQ GNA11 CDKN2A
5 12.17 TNF MAGEA3 KIT IL2 CD63
6 12.12 VEGFA TNF NRAS CD63
7 12 VEGFA TERT NRAS KIT IL2 GNAQ
8 11.72 IL2 GNAQ GNA11
9 11.69 NRAS GNAQ GNA11
10 11.69 TNF TERT NRAS IL2 CDKN2A
11 11.64 TNF KIT IL2
12 11.59 TNF KIT IL2
13 11.58 VEGFA NRAS CDKN2A
14 11.48 NRAS GNAQ GNA11
15
Show member pathways
11.45 VEGFA TNF IL2
16 11.41 NRAS GNAQ GNA11
17 11.29 TNF IL2 CDKN2A
18 11.23 VEGFA TNF NRAS

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 VEGFA TNF KIT
2 positive regulation of kinase activity GO:0033674 9.7 KIT IL2 AXL
3 positive regulation of endothelial cell proliferation GO:0001938 9.69 VEGFA PDCD6 NRAS
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.63 VEGFA TNF MAGEA3
5 positive regulation of MAP kinase activity GO:0043406 9.58 VEGFA TNF KIT
6 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.57 TNF TERT
7 developmental pigmentation GO:0048066 9.56 KIT GNA11
8 positive regulation of vascular permeability GO:0043117 9.55 VEGFA PTP4A3
9 positive regulation of protein kinase C signaling GO:0090037 9.54 VEGFA MC1R
10 somatic stem cell division GO:0048103 9.49 KIT CDKN2A
11 phototransduction, visible light GO:0007603 9.48 GNAQ GNA11
12 entrainment of circadian clock GO:0009649 9.43 GNAQ GNA11
13 establishment of protein localization to telomere GO:0070200 9.37 TERT BRCA2
14 pigmentation GO:0043473 9.33 MC1R KIT CD63
15 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.32 VEGFA PDCD6
16 regulation of vascular endothelial growth factor signaling pathway GO:1900746 9.26 PTP4A3 CD63
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.26 VEGFA TNF KIT IL2
18 positive regulation of protein kinase B signaling GO:0051897 9.02 VEGFA TNF MC1R KIT AXL

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 VEGFA TNF TERT S100B RFC5 PTP4A3
2 type 2A serotonin receptor binding GO:0031826 8.96 GNAQ GNA11

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....